Immunocore (NASDAQ:IMCR) is a pioneering biotechnology company focused on developing and commercializing a new generation of immunotherapies to improve the lives of patients with cancer and infectious diseases. Its cutting-edge platform leverages T cell receptor (TCR) technology to target and destroy cancer cells in a unique and effective way. The company's flagship project, tebentafusp, targets uveal melanoma, a rare and aggressive form of melanoma. Beyond oncology, Immunocore has an interest in infectious diseases, exemplified by its efforts to combat HIV and hepatitis B. Driven by innovation and the quest for impactful treatments, Immunocore's objective is to advance its pipeline through clinical trials to deliver life-changing therapies to those in need.